Document:

Exhibit 4.64

 

 

SECURED PROMISSORY
NOTE

 

	U.S.$6,000,000.00	Issue Date: October 5, 2016

 

THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED,
SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT
AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF
REASONABLY REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED
TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS. THIS NOTE, AND THE COMPANY'S AND HOLDER’S RIGHTS AND OBLIGATIONS HEREUNDER,
IS SUBJECT TO A SUBORDINATION AGREEMENT BETWEEN THE ORIGINAL HOLDER HEREOF, THE COMPANY, THE CREDITORS PARTY THERETO AND STEGODON
CORPORATION, AS AGENT, DATED AS OF THE ISSUE DATE. IN THE EVENT OF ANY INCONSISTENCY BETWEEN THIS NOTE AND THE SUBORDINATION AGREEMENT,
THE TERMS OF THE SUBORDINATION AGREEMENT WILL CONTROL.

 

Subject to the terms and conditions of this
Note, for value received, Amyris, Inc., a Delaware corporation (the “Company”),
hereby promises to pay to the order of Foris Ventures LLC or registered assigns
(“Holder”), the principal sum of Six Million Dollars ($6,000,000), or such lesser amount as shall then
equal the outstanding principal amount hereunder, together with interest accrued on the unpaid principal amount at the Applicable
Rate. Interest shall begin to accrue on the Issue Date set forth above, shall continue to accrue on the outstanding principal until
the entire Balance is paid, and shall be computed based on the actual number of days elapsed and on a year of 365 days.

 

This Note was issued pursuant to the Note Purchase
Agreement, dated as of October 5, 2016 (as amended from time to time, the “Agreement”), by and among
the Company, the original holder of this Note and the other parties thereto and is subject to provisions of the Agreement. Capitalized
terms used but not otherwise defined herein shall have the meaning given to such terms in the Agreement.

 

The following is a statement of the rights of
Holder and the terms and conditions to which this Note is subject, and to which the Holder hereof, by the acceptance of this Note,
agrees.

 

Notwithstanding anything to the contrary, this
Note is subordinated to certain other indebtedness of the Company on the terms and restrictions set forth in the Subordination
Agreement.

 

     

     

    

 

1.       
DEFINITION. The following definitions shall apply for purposes of this Note.

 

“Affiliate” has the
meaning ascribed to it in Rule 144 promulgated under the Securities Act.

 

“Applicable Rate”
means a rate equal to the lower of: (a) the Highest Lawful Rate; and (b) thirteen and one half percent (13.5%) per annum.

 

“Balance” means, at
the applicable time, the sum of all then outstanding principal of this Note, all then accrued but unpaid interest and all other
amounts then accrued but unpaid under this Note.

 

“Board of Directors”
means the Company’s Board of Directors.

 

“Business Day” means
a weekday on which banks are open for general banking business in San Francisco, California.

 

“Capital Lease Obligation” means, at the
time any determination thereof is to be made, the amount of the liability in respect of a capital lease that would at such time
be required to be capitalized on a balance sheet in accordance with GAAP.

 

“Change of Control”
shall mean the occurrence of any of the following: (i) the consolidation of the Company with, or the merger of the Company
with or into, another “person” (as such term is used in Rule 13d-3 and Rule 13d-5 of the Exchange Act), or the sale,
lease, transfer, conveyance or other disposition, in one or a series of related transactions, of all or substantially all of the
assets of the Company and its Subsidiaries taken as a whole, or the consolidation of another “person” with, or the
merger of another “person” into, the Company, other than in each case pursuant to a transaction in which the “persons”
that “beneficially owned” (as such term is defined in Rule 13d-3 and Rule 13d-5 under the Exchange Act), directly or
indirectly, the Voting Shares of the Company immediately prior to the transaction “beneficially own”, directly or indirectly,
Voting Shares representing at least a majority of the total voting power of all outstanding classes of voting stock of the surviving
or transferee person; (ii) the adoption by the Company of a plan relating to the liquidation or dissolution of the Company;
(iii) the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which
is that any “person” becomes the “beneficial owner” directly or indirectly, of more than 50% of the Voting
Shares of the Company (measured by voting power rather than number of shares); or (iv) the first day on which a majority of
the members of the Board of Directors does not consist of Continuing Directors.

 

“Company” shall include,
in addition to the Company identified in the opening paragraph of this Note, any corporation or other entity which succeeds to
the Company’s obligations under this Note, whether by permitted assignment, by merger or consolidation, operation of law
or otherwise.

 

“Continuing Director”
shall mean, as of any date of determination, any member of the Board of Directors who (i) was a member of the Board of Directors
on the Issue Date or (ii) was nominated for election or elected to the Board of Directors with the approval of a majority
of the Continuing Directors who were members of the Board of Directors at the time of such nomination

 

    	 	-2-	 

     

    

 

or election and who voted with respect to such
nomination or election; provided that a majority of the members of the Board of Directors voting with respect thereto shall at
the time have been Continuing Directors.

 

“Debt” shall mean,
with respect to any Person, any indebtedness of such Person, whether or not contingent, in respect of borrowed money or evidenced
by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements in respect thereof) or banker’s
acceptances or representing Capital Lease Obligations or the balance deferred and unpaid of the purchase price of any property
or representing any Hedging Obligations, except any such balance that constitutes an accrued expense or trade payable, if and to
the extent any of the foregoing indebtedness (other than letters of credit and Hedging Obligations) would appear as a liability
upon a balance sheet of such Person prepared in accordance with GAAP, as well as all Debt of others secured by a Lien on any asset
of such Person (whether or not such Debt is assumed by such Person) and Lease Debt and, to the extent not otherwise included, the
Guarantee by such Person of any Debt of any other Person. The amount of any Debt outstanding as of any date shall be (i) the
accreted value thereof, in the case of any Debt that does not require current payments of interest or (ii) the principal amount
thereof, together with any interest thereon that is more than 30 days past due, in the case of any other Debt.

 

“Event of Default” has
the meaning set forth in Section 5.

 

“Financing Document” means
each of this Note, the Notes, the Agreement and any other document entered into, executed or delivered under or in connection with,
or for the purpose of amending, any of such documents.

 

“GAAP” means generally
accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American
Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such
other statements by such other entity as have been approved by a significant segment of the accounting profession in the United
States, which are in effect from time to time.

 

“Hedging Obligations”
means, with respect to any Person, the obligations of such Person under (i) currency exchange or interest rate swap agreements,
interest rate cap agreements and interest rate collar agreements and (ii) other agreements or arrangements designed to protect
such Person against fluctuations in interest rates or currency exchange rates.

 

“Highest Lawful Rate”
means the maximum non-usurious rate of interest, as in effect from time to time, which may be charged, contracted for, reserved,
received or collected by Holder in connection with this Note under applicable law.

 

“Lease Debt” means,
with respect to any Person, (i) the amount of any accrued and unpaid obligations of such Person arising under any lease or
related document (including a purchase agreement, conditional sale or other title retention agreement) in connection with the lease
of real property or improvement thereon (or any personal property included as part of any such lease) which provides that such
Person is contractually obligated to purchase or cause a third party to purchase the leased property or pay an agreed upon residual
value of the leased property to the lessor (whether or not such lease transaction is characterized as an operating lease or a capitalized

 

    	 	-3-	 

     

    

 

lease in accordance with GAAP) and (ii) the
guarantee, direct or indirect, in any manner (including, without limitation, letters of credit and reimbursement agreements in
respect thereof), of any of the amounts set forth in (i) above.

 

“Lien” means, with
respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect of such asset,
whether or not filed, recorded or otherwise perfected under applicable law (including any conditional sale or other title retention
agreement, any lease in the nature thereof, any option or other agreement to sell or give a security interest in and any filing
of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statutes) of any jurisdiction).

 

“Lost Note Documentation”
means documentation satisfactory to the Company with regard to a lost or stolen Note, including, if required by the Company, an
affidavit of lost note and an indemnification agreement by Holder in favor of the Company with respect to such lost or stolen Note.

 

“Maturity Date” means
May 15, 2017.

 

“Note” means this
Secured Promissory Note.

 

“Notes” means a series
of secured promissory notes aggregating up to no more than $6,000,000 in original principal amount issued under the Agreement,
of which this Note is one, each such note containing substantially identical terms and conditions as this Note.

 

“Person” means an
individual, corporation, limited liability company, partnership, association, joint-stock company, trust, unincorporated organization,
joint venture or other entity or any governmental authority.

 

“Principal Balance”
means, at the applicable time, all then outstanding principal of this Note.

 

“Subordination Agreement”
means that certain Subordination Agreement dated as of October 5, 2016, by and among the Purchasers, the Company and the Agent.

 

“Subsidiary” means,
with respect to any specified Person: (a) any corporation, association or other business entity of which more than 50% of the total
voting power of shares of capital stock entitled (without regard to the occurrence of any contingency and after giving effect to
any voting agreement or stockholders’ agreement that effectively transfers voting power) to vote in the election of directors,
managers or trustees of the corporation, association or other business entity is at the time owned or controlled, directly or indirectly,
by that Person or one or more of the other Subsidiaries of that Person (or a combination thereof); and (b) any partnership (i)
the sole general partner or the managing general partner of which is such Person or a Subsidiary of such Person or (ii) the only
general partners of which are that Person or one or more Subsidiaries of that Person (or any combination thereof).

 

“Voting Shares” of
any Person means capital shares or capital stock of such Person which ordinarily has voting power for the election of directors
(or Persons performing similar functions) of such Person, whether at all times or only so long as no senior class of securities
has such voting

 

    	 	-4-	 

     

    

 

power by reason of any contingency.

 

2.        
PAYMENT AT MATURITY DATE; INTEREST. 

 

2.1         
Payment at Maturity Date.

 

(a)      
If this Note has not been previously prepaid in full pursuant to Section 3.1 prior to the Maturity Date, then the entire
Balance shall be due and payable in full in cash on the Maturity Date.

 

(b)      
All rights with respect to this Note shall terminate upon the repayment of the entire Balance of this Note as provided
in Section 2.1(a). Notwithstanding the foregoing, Holder agrees to surrender this Note to the Company (or Lost Note Documentation
where applicable) as soon as practicable after repayment pursuant to Section 2.1.

 

(c)     
Notwithstanding anything herein to the contrary, if during any period for which interest is computed hereunder, the
amount of interest computed on the basis provided for in this Note, together with all fees, charges and other payments which are
treated as interest under applicable law, as provided for herein or in any other document executed in connection herewith, would
exceed the amount of such interest computed on the basis of the Highest Lawful Rate, then the Company shall not be obligated to
pay, and Holder shall not be entitled to charge, collect, receive, reserve or take, interest in excess of the Highest Lawful Rate,
and during any such period the interest payable hereunder shall be computed on the basis of the Highest Lawful Rate.

 

3.       
Prepayment; Change of control.

 

3.1         
Prepayment. The Company may at any time, without penalty, upon at least five (5) days’ advance written
notice to Holder, prepay all or any portion of the unpaid Balance of this Note. Any such prepayment shall be applied as provided
in Section 4 below.

 

3.2          
Change of Control Payment. If the Company completes a Change of Control before the payment of the entire Balance
of this Note, then upon the closing of such Change of Control, Holder shall be entitled to be repaid the entire Balance of this
Note.

 

4.       
Notes Pari Passu; APPLICATION OF PAYMENTS. Each of the Notes shall rank equally without preference or
priority of any kind over one another, and all payments and recoveries under any other Financing Document payable on account of
principal and interest on the Notes shall be paid and applied ratably and proportionately on the Balances of all outstanding Notes
on the basis of their original principal amount. Subject to the foregoing provisions of this Section, all payments will be applied
first to the repayment of accrued fees and expenses under this Note, then to accrued interest until all then outstanding
accrued interest has been paid in full, and then to the repayment of principal until all principal has been paid in full.
If after all applications of such payments have been made as provided in this Section, then the remaining amount of such payment
that is in either case in excess of the aggregate Balance of all outstanding Notes, shall be returned to the Company.

 

    	 	-5-	 

     

    

 

5.       
EVENTS OF DEFAULT. Each of the following events shall constitute an “Event of Default”
hereunder:

 

(a)          
The Company fails to make any payment when due under this Note on the applicable due date or within five (5) days after
written notice of such failure has been given on behalf of Holder to the Company;

 

(b)          
A receiver is appointed for any material part of the Company’s property, the Company makes a general assignment
for the benefit of creditors, or the Company becomes a debtor or alleged debtor in a case under the U.S. Bankruptcy Code or becomes
the subject of any other bankruptcy or similar proceeding for the general adjustment of its debts or for its liquidation;

 

(c)           
The Company breaches any material obligation to any Holder under this Note and does not cure such breach within twenty
(20) days after written notice thereof has been given by or on behalf of such Holder to the Company;

 

(d)           
A default under any mortgage, indenture or instrument under which there may be issued or by which there may be secured
or evidenced any Debt for money borrowed by the Company (or the payment of which is guaranteed by the Company, whether such Debt
or guarantee now exists, or is created after the Issue Date of this Note, which default (a) is caused by a failure to pay principal
of or premium, if any, or interest on such Debt prior to the expiration of the grace period provided in such Debt on the date of
such default or (b) results in the acceleration of such Debt prior to its express maturity and, in each case in clause (a) or (b),
the principal amount of any such Debt, together with the principal amount of any other such Debt that has not been paid when due,
or the maturity of which has been so accelerated, aggregates $10,000,000 or more; or

 

(e)           
The Company’s Board of Directors or stockholders adopt a resolution for the liquidation, dissolution or winding
up of the Company.

 

Upon the occurrence of any Event of Default, all accrued but unpaid
expenses, accrued but unpaid interest, all principal and any other amounts outstanding under this Note shall (i) in the case of
any Event of Default under Section 5(b), become immediately due and payable in full without further notice or demand by Holder
and (ii) in the case of any Event of Default other than under Section 5(b), become immediately due and payable upon written notice
by or on behalf of all Holder(s) of then outstanding Notes. Notwithstanding any other provision of this Note, Holder agrees that
Holder will exercise Holder’s rights and remedies under this Note only in concert with all other holders of outstanding Notes
and will not take any action, including commencement or prosecution of litigation or any other proceeding to collect this Note,
except as agreed by the holders of a majority of the then outstanding principal amount of the Notes.

 

6.       
PROVISIONS RELATING TO Stockholder RIGHTS. This Note does not entitle Holder to any voting rights or other
rights as a stockholder of the Company. No

 

    	 	-6-	 

     

    

 

provisions of this Note and no enumeration herein
of the rights or privileges of Holder, shall cause Holder to be a stockholder of the Company for any purpose.

 

7.       
REPRESENTATIONS AND WARRANTIES OF HOLDER. In order to induce the Company to issue this Note to
the original Holder, the original Holder has made representations and warranties to the Company as set forth in the Agreement.

 

8.       
GENERAL PROVISIONS.

 

8.1         
Waivers. The Company and all endorsers of this Note hereby waive notice, presentment, protest and notice of dishonor.

 

8.2         
Transfer. Neither this Note nor any rights hereunder may be assigned, conveyed or transferred, in whole or in
part, without the Company’s prior written consent, which the Company may withhold in its sole discretion; provided,
however, that this Note may be assigned, conveyed or transferred without the prior written consent of the Company to
any Affiliate of Holder who (a) executes and delivers an acknowledgement that such transferee agrees to be subject to, and
bound by, all the terms and conditions of this Note, (b) makes the representations and warranties to the Company that are set forth
in Section 5 of the Agreement, and (c) (if requested by the Company) delivers to the Company an opinion of legal counsel,
reasonably satisfactory to the Company, that such transfer complies with state and federal securities laws. Subject to the foregoing,
the rights and obligations of the Company and Holder under this Note shall be binding upon and benefit their respective permitted
successors, assigns, heirs, administrators and transferees.

 

8.3         
Governing Law. This Note shall be governed, construed and interpreted in accordance with the laws of the State
of California, without giving effect to principles of conflicts of law.

 

8.4         
Headings. The headings and captions used in this Note are used only for convenience and are not to be considered
in construing or interpreting this Note. All references in this Note to sections and exhibits shall, unless otherwise provided,
refer to sections hereof and exhibits attached hereto, all of which exhibits are incorporated herein by this reference.

 

8.5         
Notices. All notices, requests, and other communications hereunder shall be in writing and will be deemed to
have been duly given and received (a) when personally delivered, (b) when sent by facsimile upon confirmation of receipt,
(c) one business day after the day on which the same has been delivered prepaid to a nationally recognized courier service,
or (d) five business days after the deposit in the United States mail, registered or certified, return receipt requested,
postage prepaid, in each case addressed, as to the Company, to Amyris, Inc., 5885 Hollis Street, Suite 100, Emeryville, CA 94608,
Attn: General Counsel, facsimile number:           , with a copy to Fenwick & West LLP, 801 California Street, Mountain View, CA
94041, Attn:           , facsimile number:           , and as to Holder at the address and facsimile number set forth opposite such Holder’s
name on Schedule I to the Agreement or as otherwise indicated by Holder by providing notice of a change in its address,
facsimile number, or other information to the Company. Holder and the Company may each agree in writing to accept notices and other
communications to it hereunder by electronic

 

    	 	-7-	 

     

    

 

communications pursuant to procedures reasonably
approved by it; provided that approval of such procedures may be limited to particular notices or communications.

 

8.6         
Place of Payment. Payments of the Principal and any interest and other payments hereunder shall be delivered
to the Holder at the address specified in the Agreement or at such other address or the attention of such other Person as specified
by prior written notice to the Company, including any transferee of this Note.

 

8.7         
Amendments and Waivers. This Note and all other Notes issued under
the Agreement may be amended and provisions may be waived by the Note holders holding at least a majority of the then outstanding
principal amount of Notes and the Company as provided in Section 10(j) of the Agreement. Any amendment or waiver effected
in accordance with Section 10(j) of the Agreement shall be binding upon each holder of any Notes at the time outstanding, each
future holder of the Notes and the Company.

 

8.8         
Severability. If one or more provisions of this Note are held to be unenforceable under applicable law, then
such provision(s) shall be excluded from this Note to the extent they are held to be unenforceable and the remainder of the Note
shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms.

 

[Signature page follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	-8-	 

     

    

 

IN WITNESS WHEREOF, the Company has caused this Secured Promissory
Note to be signed in its name as of the date first written above.

 

 

	 	THE COMPANY	 
	 	 	 
	 	AMYRIS, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Raffi Asadorian	 
	 	 	 	 
	 	Name: Raffi Asadorian	 
	 	 	 	 
	 	Title: Chief Financial Officer	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-9-Exhibit 4.65

 

CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

CREDIT AGREEMENT 

 

This CREDIT AGREEMENT, dated as of 26 October 2016 (as amended,
modified or supplemented from time to time, this “Agreement”), is entered into by and between AMYRIS, INC.,
a Delaware corporation, whose principal place of business is 5885 Hollis Street, Ste. 100, Emeryville, California 94608 (the “Company”),
and GUANFU HOLDING CO., LTD., a company duly established and validly existing under the laws of the People’s Republic
of China, whose registered address is Tuban Village, Xunzhong Town, Dehua, Quanzhou City, Fujian Province (the “Lender”).
In order to fulfill this Credit Agreement, Lender is about to make its subsidiary be the entity to accomplish the obligations and
as the Lender, so “Lender” hereinafter refers to “Guanfu or its subsidiary”.

 

 

RECITALS 

 

    A.  In connection with the business cooperation between
the Company and the Lender, the Lender has agreed to purchase from the Company, and the Company has agreed to sell to the Lender,
one or more unsecured notes having an aggregate principal amount of not greater than $25,000,000 (each, a “Note”,
and collectively, the “Notes”).

 

B.  Capitalized terms not defined in Section 7 hereof
or otherwise defined herein shall have the meaning set forth in the form of Note (as defined below) attached hereto as Exhibit A.

 

C. The Company agrees to grant the Lender’s subsidiary, Nenter & Co., Inc.
(“Nenter”) the global exclusive purchase right with regard to the Farnesene solely to produce vitamin E upon the Effective
Date (defined below), and such global exclusive purchase right is permanent and remains effective after the expiration of this
Agreement. The Company will not, directly or indirectly, sell Farnesene for the purposed manufacture of Vitamin E to any other
vitamin E or vitamin E ingredients manufacturers other than Nenter, and will satisfy Nenter’s purchase quantities.

 

AGREEMENT 

 

    NOW THEREFORE, in consideration of the foregoing, and the representations,
warranties, and conditions set forth below, the parties hereto, intending to be legally bound, hereby agree as follows:

 

    1.  Purchase and Sale of The Notes.  

 

		(a)	The sale and purchase of each of the Notes shall take place at one or more but no more than three closings (each, a “Closing”),
each to be held at such place and time as the Company and the Lender may determine in accordance with Section 1(b) (each, a “Closing
Date”). At each Closing, the Company will deliver to the Lender the Notes to be purchased by the Lender at such Closing,
against receipt by the Company of the principal amount of the Notes to be sold by the Company at such Closing. The Notes shall,
in the aggregate, sum up to no more than $25,000,000. Each of the Notes will be registered in the Lender’s name in the Company’s
records.

 

		(b)	The initial Closing shall be held on December 1, 2016, unless the Lender shall notify the Company in writing by not later than
November 22, 2016 that the initial Closing shall be held on a later date, which date shall be no later than December 31, 2016.
The Company shall notify the Lender of the principal amount of the Note to be purchased and sold at the initial Closing in writing
by no later than five days before the initial Closing. In the event the principal amount of the Note purchased and sold at the
initial Closing shall be less than $25,000,000, each subsequent Closing shall be held on not less than sixty (60) days prior written
notice by the Company to the Lender, which notice shall specify the date of such subsequent Closing and the principal amount of
the Note to be purchased and sold at such subsequent Closing.

 

     

     

    

 

    2.  Representations and Warranties of the Company.  The
Company represents and warrants to the Lender as of the date hereof and as of the date of each Closing that:

 

		(a)	Due Incorporation, Qualification, etc.  Each of the Company and its Subsidiaries (i) is a corporation
duly organized, validly existing and in good standing under the laws of its state of incorporation; (ii) has the power and
authority to own, lease and operate its properties and carry on its business as now conducted; and (iii) is duly qualified,
licensed to do business and in good standing as a foreign corporation in each jurisdiction where the failure to be so qualified
or licensed could reasonably be expected to have a Material Adverse Effect.

 

		(b)	Authority.  Upon the Company’s Board approval, the execution, delivery and performance by the Company
of this Agreement and each Note executed by the Company and the consummation by the Company of the transactions contemplated hereby
and thereby (i) are within the power of the Company and (ii) have been duly authorized by all necessary corporate actions
on the part of the Company.

 

		(c)	Enforceability.  This Agreement and each Note executed by the Company has been duly executed and delivered
by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance
with its respective terms, except in each case as may be limited by bankruptcy, insolvency or other laws of general application
relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

		(d)	Non-Contravention.  The execution and delivery by the Company of this Agreement and each Note executed by
the Company and the performance and consummation by the Company of the transactions contemplated hereby and thereby do not and
will not (i) violate the certificate of incorporation or bylaws of the Company or any judgment, order, writ, decree, statute,
rule or regulation applicable to the Company; (ii) violate any provision of, or result in the breach or the acceleration
of, or entitle any other Person to accelerate (whether after the giving of notice or lapse of time or both), any mortgage, indenture,
agreement, instrument or contract to which the Company is a party or by which it is bound except to the extent such violation,
breach or acceleration could not reasonably be expected to result in a Material Adverse Effect; or (iii) result in the creation
or imposition of any Lien upon any property, asset or revenue of the Company or the suspension, revocation, impairment, forfeiture,
or nonrenewal of any permit, license, authorization or approval applicable to the Company, its business or operations, or any of
its assets or properties except to the extent such suspension, revocation, impairment, forfeiture or nonrenewal could not reasonably
be expected to have a Material Adverse Effect.

 

		(e)	Approvals. Except for approval of this Agreement from the Company’s Board and the transactions contemplated
thereby, no consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority
or other Person is required in connection with the execution and delivery by the Company of this Agreement and each Note executed
by the Company and the performance and consummation by the Company of the transactions contemplated hereby and thereby, except
for those already obtained or those that will be obtained prior to the Effective Date or the execution of such Note, as applicable.

 

		(f)	No Violation or Default.  None of the Company or any of its Subsidiaries is in violation of or in default
with respect to (i) its certificate of incorporation or bylaws or any judgment, order, writ, decree, statute, rule or
regulation applicable to such Person; or (ii) any mortgage, indenture, agreement, instrument or contract to which such Person
is a party or by which it is bound (nor is there any waiver in effect which, if not in effect, would result in such a violation
or default), where, in each case, such violation or default, individually, or together with all such violations or defaults, could
reasonably be expected to have a Material Adverse Effect.

 

		(g)	Litigation.  No actions (including, without limitation, derivative actions), suits, proceedings or investigations
are pending or, to the actual knowledge of the Company, threatened against the Company or any of its Subsidiaries at law or in
equity in any court or before any other governmental

 

    	 	2	 

     

    

 

		 	
authority which if adversely determined (i) would (alone or in the aggregate) have a Material Adverse Effect or (ii) seeks
to enjoin, either directly or indirectly, the execution, delivery or performance by the Company of this Agreement and each Note
or the transactions contemplated hereby and thereby.

 

		(h)	Properties. Each of the Company and its Subsidiaries owns or leases all such properties, including lands, buildings,
machinery and production equipment, as are necessary to the conduct of its operations as presently conducted, and such properties
are free of any Liens other than as disclosed in the Company’s public filings. Neither the Company nor any of its Subsidiaries
has received any notice of proceedings relating to its properties which, singly or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would have a Material Adverse Effect.

 

		(i)	Labor. No labor problem or dispute with the employees, including management, of the Company or any of its Subsidiaries
exists or is threatened or imminent, except as would not have a Material Adverse Effect.

 

		(j)	Commission Filings. The Company has timely filed (subject to 12b-25 filings with respect to certain periodic filings)
all reports, schedules, forms, statements and other documents required to be filed by it with the U.S. Securities and Exchange
Commission (the “Commission”) pursuant to the reporting requirements of the U.S. Securities Exchange Act of
1934, as amended (the “Exchange Act”) (all of the foregoing filed with the Commission prior to the date hereof
and all financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred
to herein as the “SEC Documents”). As of their respective dates, the SEC Documents complied in all material
respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder applicable
to the SEC Documents, and none of the SEC Documents, at the time they were filed with the Commission, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. In addition, as of each Closing, the SEC Documents,
together with any additional documents filed with the Commission after the date hereof and through the date of such Closing, when
taken in their entirety, shall not contain any untrue statements of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in light of the date upon which they were made and the
circumstances under which they were made, not misleading.  

 

		(k)	Intellectual Property.

 

		(i)	All domestic and foreign patents, patent applications, copyrighted works, copyright applications, and registrations, trade
names, trademarks and service marks, registered trademarks, and trademark applications, registered service marks and service mark
applications which are or may be used by and owned or co-owned by the Company in connection with farnesene manufacturing (collectively,
the “Intellectual Property”) are listed in Schedule I, which Schedule indicates, with respect to each, the nature
of the Company’s interest therein.

 

		(ii)	The Intellectual Property owned exclusively by the Company is free and clear of any Liens that would prohibit the Company from
granting the license for the Intellectual Property described in this Agreement.

 

		(iii)	Except for the pending opposition proceedings concerning the Company’s European patent no. EP2021486 (AM-700 EP) and
European patent no. EP2217711 (AM-1400 EP) further described in the Cooperation Agreement, to the actual knowledge of the Company,
none of the Intellectual Property is the subject of any lawsuit or arbitration proceeding. The Company has no actual knowledge
of any infringement by the Company of valid third party patent or other intellectual property relating to the production of farnesene
for the manufacture of Vitamin E.

 

    	 	3	 

     

    

 

		(l)	Other Regulations.  None of the Company or its Subsidiaries is subject to regulation under the U.S. Investment
Company Act of 1940 or to any federal or state statute or regulation limiting its ability to incur indebtedness.

 

		(m)	GMO-free verification. The Company will apply for a GMO-free verification regarding its farnesene for vitamin E.

 

		(n)	No Note registration. The Company is under no obligation to effect any registration of the Notes under the U.S. Securities
Act of 1933, as amended (the “Securities Act”), or any state securities laws with respect to the Notes or to
file for or comply with any exemption from registration. 

 

    3.  Representations and Warranties of the Lender.  The
Lender represents and warrants to the Company as of the date hereof and as of the date of each Closing that:

 

		(a)	Binding Obligation.  Except for that the approval from the shareholder’s meeting and governmental authority
to be obtained by the Lender, the Lender has full legal capacity, power and authority to execute and deliver this Agreement and
to perform its obligations hereunder. This Agreement and each Note issued to the Lender is a valid and binding obligation of the
Lender, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application
relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

		(b)	Securities Law Compliance.   The Lender is purchasing the Notes to be acquired by the Lender hereunder for
its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution
thereof. Lender has received or has had full access to all of the information necessary and appropriate to make an informed investment
decision. The Lender is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities
Act. The Lender acknowledges that it can bear the economic risk of the investment the Notes.

 

		(c)	Approvals. Except for that the approval from the shareholder’s meeting and governmental authority to be obtained
by Lender, no consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority
or other Person is required in connection with the execution and delivery by the Lender of this Agreement and the performance and
consummation by the Lender of the transactions contemplated hereby and thereby, except for those already obtained.

 

		(d)	Source of Funds. The funds provided by the Lender to the Company in connection with this Agreement and
the Notes are in full compliance with the money laundering statutes of all jurisdictions to which the Lender is subject, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency having jurisdiction over the Lender.

 

		(e)	No Note registration. The Lender is under no obligation to effect any registration of the Notes under the Securities
Act, or any state securities laws with respect to the Notes or to file for or comply with any exemption from registration. 

 

    4.  Conditions to Obligations of the Lender.  The
Lender’s obligations at each Closing are subject to the fulfillment, on or prior to each Closing Date, of all of the following
conditions, any of which may be waived in whole or in part by the Lender:

 

		(a)	Representations and Warranties.  The representations and warranties made by the Company in Section 2
hereof shall have been true and correct when made, and shall be true and correct on such Closing Date.

 

		(b)	Governmental Approvals and Filings.  Except for any notices required or permitted to be filed after such Closing
Date with certain federal and state securities commissions, the Company shall have obtained all governmental approvals required
in connection with the lawful sale and issuance of the Note being purchased and sold at such Closing.

 

    	 	4	 

     

    

 

		(c)	Legal Requirements.  At such Closing, the sale and issuance by the Company, and the purchase by the Lender,
of the applicable Note shall be legally permitted by all laws and regulations to which the Lender or the Company is subject.

 

		(d)	Transaction Documents.  The Company shall have duly executed and delivered to the Lender this Agreement and
the Note being purchased and sold at such Closing.

 

    5.  Conditions to Obligations of the Company.  The
Company’s obligations at each Closing are subject to the fulfillment, on or prior to each Closing Date, of the following
conditions, any of which may be waived in whole or in part by the Company:

 

		(a)	Representations and Warranties.  The representations and warranties made by the Lender in Section 3 hereof
shall be true and correct when made, and shall be true and correct on such Closing Date.

 

		(b)	Governmental Approvals and Filings.  Except for any notices required or permitted to be filed after such Closing
Date with certain federal and state securities commissions, the Lender shall have obtained all governmental approvals required
in connection with the lawful sale and issuance of the Note being purchased and sold at such Closing.

 

		(c)	Legal Requirements.  At such Closing, the sale and issuance by the Company, and the purchase by the Lender,
of the applicable Note shall be legally permitted by all laws and regulations to which the Lender or the Company are subject.

 

		(d)	Purchase Price.  The Lender shall have delivered to the Company the principal amount of the Note being
purchased by the Lender at such Closing.

 

		(e)	The Company shall have obtained all approvals required in connection with this this Agreement and the transaction contemplated
hereby

 

    6.  Covenant of the Lender.  So
long as the Lender holds any Note, the Lender agrees that it will not engage in any short selling of the Company’s Common
Stock. Nothing in this Section 6 will restrict the ability of the Lender to sell or purchase shares of the Company’s Common
Stock in open market transactions.

 

    7.  Definitions.  As used in
this Agreement, the following capitalized terms have the following meanings:

 

“Effective Date” means the latter of
(i) the date of the shareholders’ meeting whereby Guanfu Holding Co., Ltd., the sole shareholder of Nenter, approves this
Agreement; (ii) the date on which government approval is obtained by Guanfu; or (iii) the date of approval of this Agreement from
the Company’s Board.

 

“Lien” means, with respect to any property,
any security interest, mortgage, pledge, lien, claim, charge or other encumbrance in, of, or on such property or the income therefrom,
including, without limitation, the interest of a vendor or lessor under a conditional sale agreement, capital lease or other title
retention agreement, or any agreement to provide any of the foregoing, and the filing of any financing statement or similar instrument
under the Uniform Commercial Code or comparable law of any jurisdiction.

 

“Material Adverse Effect” means a material
adverse effect on the ability of the Company to pay or perform the Obligations in accordance with the terms of the Notes and to
avoid an Event of Default, or an event which, with the giving of notice or the passage of time or both, would constitute an Event
of Default.

 

“Obligations” means all loans, advances,
debts, liabilities and obligations, howsoever arising, owed by the Company to the Lender under the Notes of every kind and
description (whether or not

 

    	 	5	 

     

    

 

evidenced by any note or instrument and whether or not for the payment of money), now existing or hereafter arising under or pursuant
to the terms of the Notes, including all principal, interest, fees, charges, expenses, attorneys’ fees and costs and accountants’
fees and costs chargeable to and payable by the Company thereunder, in each case, whether direct or indirect, absolute or contingent,
due or to become due, and whether or not arising after the commencement of a proceeding under Title 11 of the United States
Code (11 U.S.C. Section 101 et seq.), as amended from time to time (including post-petition interest) and whether or
not allowed or allowable as a claim in any such proceeding.

 

    8.  Miscellaneous.  

 

		(a)	Waivers and Amendments.  Any provision of this Agreement may be amended, waived or modified only upon the
written consent of the Company and the Lender.

 

		(b)	Governing Law.  This Agreement and all actions arising out of or in connection with this Agreement shall be
governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions
of the State of Delaware or of any other jurisdiction.

 

		(c)	Arbitration. Any dispute, controversy or claim arising out of or relating to this Agreement or the Notes or the subject
matter hereof or thereof, including, but not limited to, any contractual, pre-contractual or non-contractual rights, obligations
or liabilities and any question or dispute regarding the existence, validity, formation, effect, interpretation, performance, breach,
termination or invalidity hereof or thereof (a “Dispute”), shall be finally settled by arbitration. The place
of arbitration shall be the Hong Kong International Arbitration Centre (“HKIAC”), and the arbitration shall be conducted
and administered in accordance with the arbitration rules of HKIAC in effect at the time of applying for arbitration (“HKIAC
Arbitration Rules”), which HKIAC Rules are deemed to be incorporated by reference in this Section 8(c). The arbitration
tribunal shall consist of three (3) arbitrators, one (1) to be appointed by the claimant, one (1) to be appointed by the respondent
and the two (2) arbitrators so appointed shall jointly appoint the third arbitrator. The language for the arbitration (including
but not limited to the arbitral proceedings, all submissions and written evidence, and any arbitral award rendered) shall be English
and the place for arbitration shall be Hong Kong. The tribunal shall decide any dispute submitted by the parties strictly in accordance
with the substantive law of the State of Delaware and shall not apply any other substantive law. Subject to the agreement of the
tribunal, any Dispute(s) which arise subsequent to the commencement of arbitration of any existing Dispute(s) shall be resolved
by the tribunal already appointed to hear the existing Dispute(s). The arbitration award shall be final, conclusive and binding
on each party as from the date rendered. Judgment upon any arbitration award may be entered and enforced in any court having jurisdiction
over a party or any of its assets.

 

		(d)	Survival.  The representations, warranties, covenants and agreements made herein shall survive the execution
and delivery of this Agreement.

 

		(e)	Successors and Assigns.  Subject to the restrictions on transfer described in Sections 8(f) and 8(g) below,
the rights and obligations of the Company and the Lender hereunder and under the Notes shall be binding upon and inure to the benefit
of the successors, assigns, heirs, administrators and transferees of the parties.

 

		(f)	Registration, Transfer and Replacement of the Notes.  The Notes issuable under this Agreement shall be issued
in registered form. The Company will keep, at its principal executive office, books for the registration and registration of transfer
of the Notes. Prior to presentation of any Note for registration of transfer, the Company shall treat the Person in whose name
such Note is registered as the owner and holder of such Note for all purposes whatsoever, whether or not such Note shall
be overdue, and the Company shall not be affected by notice to the contrary. Subject to any restrictions on or conditions to transfer
set forth in any Note, the holder of any Note, at its option, may in person or by duly authorized attorney surrender the same for
exchange at the Company’s chief executive office, and promptly thereafter and at the Company’s expense, except as provided
below, receive in exchange therefor one

 

    	 	6	 

     

    

 

		 	or more new Note(s), each in the principal requested by such holder, dated the date to which interest shall have been paid
on the Note so surrendered or, if no interest shall have yet been so paid, dated the date of the Note so surrendered
and registered in the name of such Person or Persons as shall have been designated in writing by such holder or its attorney for
the same principal amount as the then unpaid principal amount of the Note so surrendered. Upon receipt by the Company of
evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note and
(a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to it; or (b) in the case of mutilation,
upon surrender thereof, the Company, at its expense, will execute and deliver in lieu thereof a new Note executed in the
same manner as the Note being replaced, in the same principal amount as the unpaid principal amount of such Note and
dated the date to which interest shall have been paid on such Note or, if no interest shall have yet been so paid, dated
the date of such Note.

 

		(g)	Assignment by the Company; Assignment by the Lender.  Neither this Agreement nor the Notes nor any of the
rights, interests or obligations hereunder or thereunder may be assigned, by operation of law or otherwise, in whole or in part,
by the Company without the prior written consent of the Lender. The Lender will not assign, by operation of law or otherwise, this
Agreement or the Notes or any of its rights, interests or obligations hereunder or thereunder without the prior written consent
of the Company, except to its Subsidiaries.

 

		(h)	Entire Agreement.  This Agreement, Schedule I hereto, together with the Notes constitute the full and entire
understanding and agreement and supersedes any previous written or verbal agreements between the parties with regard to the subject
matter hereof and thereof.

 

		(i)	Notices.  Any notice, request or other communication required or permitted hereunder shall be in writing and
shall be deemed to have been duly given if delivered personally or by commercial delivery service, or sent via telecopy (receipt
confirmed) to the parties at the following addresses or telecopy numbers (or at such other address or telecopy numbers for a party
as shall be specified by like notice):

 

If to the Company, to:

 

Amyris, Inc.

5885 Hollis St., Ste. 100

Emeryville, CA 94608

Attention: General Counsel

Telecopy No.: 

 

with a copy to:

 

Shearman & Sterling LLP

535 Mission St., 25th Floor

San Francisco, CA 94105

Attention: 

Telecopy No.: 

 

If to the Lender, to:

 

Guanfu Holding Co., Ltd.

Tuban Village, Xunzhong Town,

Dehua, Quanzhou City, Fujian Province

Attention: Secretary of the Board of Directors

Telecopy No.: 

 

with a copy to:

 

    	 	7	 

     

    

 

Nenter & Co., Inc

197 Oriental Road, High Tech Development Zone

 

Jingzhou, Hubei Province, 434000

Attention:General Manager

Telecopy No.: 

 

 

		(j)	Severability of this Agreement.  If any provision of this Agreement shall be judicially determined to be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected
or impaired thereby.

 

		(k)	Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be an original,
but all of which together shall be deemed to constitute one instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

 

 

 

 

 

 

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered
by their proper and duly authorized officers as of the date and year first written above.

 

	 	COMPANY:	 
	 	 	 	 
	 	AMYRIS, INC.	 
	 	 	 	 
	 	By:	/s/ Raffi Asadorian  	 
	 	Name:	Raffi Asadorian	 
	 	Title:	Chief Financial Officer	 
	 	 	 	 
	 	LENDER:	 
	 	 	 	 
	 	GUANFU HOLDING CO., LTD.
	 	 	 	 
	 	By:	/s/ Lin Wen Zhi	 
	 	Name:	Lin Wen Zhi	 
	 	Title:	GENERAL MANAGER	 

 

 

 

 

 

 

 

 

 

 

 

    	 	9	 

     

    

 

EXHIBIT A

FORM OF NOTE 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

SCHEDULE I

 

[List of Intellectual Property]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

 

Intellectual Property Portfolio

as of: September 29, 2016

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	 	 	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*] Certain
portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

 

    	AMYRIS CONFIDENTIAL INFORMATION	1	 

     

    

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	
         

         

        [*] Certain portions denoted
        with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
        has been requested with respect to the omitted portions.

 

    	AMYRIS CONFIDENTIAL INFORMATION	2	 

     

    

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	
         

         

        [*] Certain portions denoted
        with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
        has been requested with respect to the omitted portions.

         

 

    	AMYRIS CONFIDENTIAL INFORMATION	3	 

     

    

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	 	 
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	 	 
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	 	 
	[*]	[*]	[*]	 	 	 	 	 
	[*]	[*]	[*]	 	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	 	[*]	[*]	 	 
	[*]	[*]	[*]	 	 	 	[*]	[*]
	[*]	[*]	[*]	 	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	[*]	[*]
	
         

         

        [*] Certain portions denoted
        with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
        has been requested with respect to the omitted portions.

 

    	AMYRIS CONFIDENTIAL INFORMATION	4	 

     

    

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	
         

        -----------------------

         

        1 [*]

         

         

         

        [*] Certain portions denoted
        with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment
        has been requested with respect to the omitted portions.

 

    	AMYRIS CONFIDENTIAL INFORMATION	5	 

     

    

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	
         

         

        -----------------------

         

        2 [*]

         

         

         

        [*] Certain portions denoted
with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

    	AMYRIS CONFIDENTIAL INFORMATION	6	 

     

    

 

	Amyris Ref	Title	Application No.	File Date	Pub Number	Pub Date	Patent Number	Issue Date
	[*]	[*]	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]
	[*]	[*]	[*]	[*]	 	 	 	[*]

 

 

-----------------------

 

3 [*]

 

4 [*]

 

 

 

[*] Certain portions denoted with
an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

 

	AMYRIS CONFIDENTIAL INFORMATION`	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]